

CYTOLOGY and MOLECULAR PATHOLOGY REPORT

Cytology Lab Director: Kai Ni, M.D. Molecular Lab Director: Derek Marsee, M.D.,Ph.D 3301 C Street, Ste 200E Sacramento, CA 95816 (916) 446-0424 Fax: (916) 446-9330 www.dpmginc.com

Patient: **TEST, PATIENT** Age: 45 (02/23/76) Pathology #: **TPC-21-34475**

Acct#: Sex: FEMALE

Doctor: Dpmg test Date Obtained: 10/04/2021

3301 C Street #200E Date Received: 10/05/2021 Sacramento, CA 95816

SPECIMEN: ThinPrep CLINICAL DATA:

Cytologic and Molecular Results:

PAP DIAGNOSIS: ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE (ASC-US)

MOLECULAR RESULTS:

HIGH RISK HPV RESULT: ***DETECTED****

CHLAMYDIA TRACHOMATIS RESULTS: not detected NEISSERIA GONORRHOEAE RESULTS: not detected TRICHOMONAS VAGINALIS RESULTS: not detected

Additional Cytologic Findings

SPECIMEN ADEQUACY: Satisfactory for evaluation. Endocervical/transformation zone component present

Prior PAP Smear Diagnoses: (3 most recent)

DATE PATHOLOGY# PAP DIAGNOSIS MOLECULAR DIAGNOSES

01/28/21 TPC-21-03223 ASC-H High Risk HPV Positive,GC Negative,Chlamydia Negative

10/16/20 TPC-20-29123 LGSIL High Risk HPV Positive

09/04/20 TPC-20-24114 LGSIL GC Negative, Chlamydia Negative

This summary of up to the most recent 3 Pap test results DOES NOT include comments about organisms seen on the Pap test, endometrial cells in the post-menopausal setting, or any other tissue studies performed. The provider must refer to the complete Pap test report or the clinical laboratory report for these items. This summary ONLY includes results of Pap tests or molecular tests performed by DPMG and does not include results from other institutions or laboratories.

The PAP smear is a screening test for cervical cancer with an inherent and irreducible false negative rate, the consequences of which may be minimized by obtaining regular annual PAP smears.

Molecular testing was performed with either the APTIMA HPV Assay kit for the 14 high-risk types of HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 (does not discriminate between the 14 high-risk types), APTIMA HPV 16 18/45 Genotype Assay kit, APTIMA Combo 2 (CT/GC) Assay kit, APTIMA Trichomonas vaginalis Assay kit, APTIMA Bacterial Vaginosis Assay kit, APTIMA CVTV Assay kit for the detection of Candida Species, Candida Glabrata and Trichomonas, and/or the APTIMA Herpes Simplex virus types 1 & 2 Assay kit. All Assays have been FDA approved and are performed according to the manufacturers specifications. The laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.

Initial Evaluation on 10/09/2021 by **Guohu (George) Li CT(ASCP)** Electronically signed at Diagnostic Pathology Medical Group, Inc 3301 C Street, Suite 200E SACRAMENTO, CA 95816

Molecular Diagnosis on 10/12/2021 by Kamalpreet Sangha CT(ASCP)

Electronically signed at Diagnostic Pathology Medical Group, Inc 3301 C Street, Suite 200E SACRAMENTO, CA 95816

Gyn Interpretation on 10/12/2021 by **Kai Ni, M.D.** Electronically signed at Diagnostic Pathology Medical Group, Inc 3301 C Street, Suite 200E SACRAMENTO, CA 95816